Correction for Shahriar et al., Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections Published: 2024 Pharmacology Correction for “Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections,” by Imrul Shahriar, Mohini Kamra, Ananda Kumar Kanduluru, Charity Lynn Campbell, Thanh Hiep Nguyen, Madduri Srinivasarao, and Philip S. Low, which published September 30, 2024; 10.1073/pnas.2408469121 (Proc. Natl. Acad. Sci. U.S.A. 121, e2408469121). The authors note there is a minor typographical mistake in the chemical structures in Scheme 2 within the SI Appendix and a minor typographical mistake in the first paragraph of the Discussion section. Regarding the mistake in the Discussion section, the authors explain, “The first paragraph of the Discussion section that mentions ‘all three neuraminidase inhibitors (i.e., oseltamivir, zanamivir, baloxavir)’ which might be confusing to the reader as baloxavir is not a neuraminidase inhibitor; it is a cap-dependent endonuclease inhibitor. Instead, if we mention ‘all three direct-acting antivirals (i.e., oseltamivir, zanamivir, baloxavir),’ that would be more appropriate.” These mistakes were discovered by the authors while reading the published article. In regard to the typographical mistake within the Discussion section, the authors explain, “It most likely won’t have too much impact on an informed reader as it is very well known in the field that baloxavir is not a neuraminidase inhibitor; readers will easily recognize it as a typographical mistake, but still, we would like to correct it if possible to avoid any confusion.” The mistake within Scheme 2 might confuse readers who are skilled in organic synthesis; however, it does not impact the conclusions. As a result, the below changes have been made. Minor changes have been made to the chemical structures in Scheme 2 within the SI Appendix. The SI Appendix has been corrected online. On page 7 of the main manuscript, right column, first full paragraph, lines 18–26, “That this recruitment of antibodies provides the major contribution to therapeutic efficacy was documented by two observations, namely that 1) all three neuraminidase inhibitors (i.e., oseltamivir, zanamivir, baloxavir) lowered viral titers 24 h after administration by only 0- to 100-fold, whereas zanDR reduced titers by >10,000-fold, and 2) zanDR prevented all mice from dying due to infection with 10× LD50 influenza virus, whereas oseltamivir, zanamivir, and baloxavir only promoted survival of 20%, 40%, and 60% of the same infected mice” should instead appear as “That this recruitment of antibodies provides the major contribution to therapeutic efficacy was documented by two observations, namely that 1) all three direct-acting antivirals (i.e., oseltamivir, zanamivir, baloxavir) lowered viral titers 24 h after administration by only 0- to 100-fold, whereas zanDR reduced titers by >10,000-fold, and 2) zanDR prevented all mice from dying due to infection with 10× LD50 influenza virus, whereas oseltamivir, zanamivir, and baloxavir only promoted survival of 20%, 40%, and 60% of the same infected mice.” The online version has been corrected.